肾移植的最新进展：笛卡尔顾问委员会的观点。
Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board.
机构信息
Department of Nephrology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.
Department of Nephrology, Medical University of Vienna, Vienna, Austria.
出版信息
Nephrol Dial Transplant. 2018 Oct 1;33(10):1699-1707. doi: 10.1093/ndt/gfx365.
Abstract
Transplantation medicine is a rapidly evolving field. Keeping afloat of the published literature to offer the best clinical care to our patients is a daunting task. As part of its educational mission, the Descartes advisory board identified seven topics in kidney transplantation where there has been substantial progresses over the last years: kidney allocation within Eurotransplant; kidney exchange strategies; kidney machine perfusion strategies; the changing landscape of anti-human leukocyte antigen (HLA) antibodies; the new immunosuppressive drugs in the pipeline; strategies for immunosuppression minimization; and the continuous enigma of focal segmental glomerular sclerosis recurrence after transplantation. Here, we have summarized the main knowledge and the main challenges of these seven topics with the aim to provide transplant professionals at large with key bullet points to successfully understand these new concepts.
摘要
移植医学是一个快速发展的领域。要想为患者提供最佳的临床护理，就需要跟上已发表文献的步伐，这是一项艰巨的任务。作为其教育使命的一部分，Descartes 顾问委员会确定了过去几年中在七个肾脏移植领域取得实质性进展的主题：在 Eurotransplant 中的肾脏分配；肾脏交换策略；肾脏机器灌注策略；抗人类白细胞抗原 (HLA) 抗体的不断变化的格局；新的免疫抑制剂药物；免疫抑制最小化策略；以及移植后局灶节段性肾小球硬化症复发的持续谜团。在这里，我们总结了这七个主题的主要知识和主要挑战，旨在为广大移植专业人员提供关键要点，以成功理解这些新概念。
相似文献
1
Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board.肾移植的最新进展：笛卡尔顾问委员会的观点。
Nephrol Dial Transplant. 2018 Oct 1;33(10):1699-1707. doi: 10.1093/ndt/gfx365.
2
Successful Treatment With Abatacept in Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplant.肾移植后复发性局灶节段性肾小球硬化症使用阿巴西普治疗成功
Exp Clin Transplant. 2019 Jan;17(Suppl 1):178-180. doi: 10.6002/ect.MESOT2018.P53.
3
A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.1例肾移植后复发性局灶节段性肾小球硬化症伴哥伦比亚分类中的变异转换
Nephrology (Carlton). 2015 Jul;20 Suppl 2:96-100. doi: 10.1111/nep.12457.
4
It is time to revise the kidney allocation system to restore the pediatric advantage.是时候修订肾脏分配系统以恢复儿科优势了。
Am J Transplant. 2018 Sep;18(9):2365-2366. doi: 10.1111/ajt.14898. Epub 2018 May 22.
5
Kidney transplantation outcomes in patients with IgA nephropathy and other glomerular and non-glomerular primary diseases in the new era of immunosuppression.免疫抑制新时代下 IgA 肾病及其他肾小球和非肾小球原发性疾病患者的肾移植结局。
PLoS One. 2021 Aug 17;16(8):e0253337. doi: 10.1371/journal.pone.0253337. eCollection 2021.
6
Kidney transplantation after rescue allocation-meticulous selection yields the chance for excellent outcome.肾移植后抢救性分配——精心选择可获得极佳效果的机会。
Nephrol Dial Transplant. 2021 Feb 20;36(3):551-560. doi: 10.1093/ndt/gfaa286.
7
Racial equity in renal transplantation. The disparate impact of HLA-based allocation.肾移植中的种族公平。基于人类白细胞抗原（HLA）分配的不同影响。
JAMA. 1993 Sep 15;270(11):1352-6.
8
Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report.复发性局灶节段性肾小球硬化症与阿巴西普：病例报告
Exp Clin Transplant. 2016 Aug;14(4):456-9. doi: 10.6002/ect.2014.0154. Epub 2014 Nov 27.
9
FK 506 and successful pregnancy in a patient after renal transplantation.肾移植患者使用FK 506与成功妊娠
Transplant Proc. 1998 Feb;30(1):163-4. doi: 10.1016/s0041-1345(97)01220-7.
10
Precision Medicine and Personalized Approach to Renal Transplantation.精准医学与肾脏移植的个体化方法。
Semin Nephrol. 2018 Jul;38(4):346-354. doi: 10.1016/j.semnephrol.2018.05.005.
引用本文的文献
1
Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study.器官移植中使用的生物免疫抑制诱导剂的无效率：一项药物警戒研究。
J Clin Med. 2025 May 13;14(10):3409. doi: 10.3390/jcm14103409.
2
Assessing Risk Factors and Posttransplant Outcomes of Nonadherence Among Kidney Transplant Recipients.评估肾移植受者不依从性的风险因素及移植后结局
Transplant Direct. 2025 May 12;11(6):e1799. doi: 10.1097/TXD.0000000000001799. eCollection 2025 Jun.
3
Outcomes in older kidney recipients from older donors: A propensity score analysis.老年供体的老年肾移植受者的结局：一项倾向评分分析。
Front Nephrol. 2022 Oct 20;2:1034182. doi: 10.3389/fneph.2022.1034182. eCollection 2022.
4
Ex Vivo Perfusion of Porcine Pancreas and Liver Sourced from Commercial Abattoirs after Circulatory Death as a Research Resource: A Methodological Study.作为一种研究资源，对循环死亡后取自商业屠宰场的猪胰腺和肝脏进行体外灌注：一项方法学研究。
Methods Protoc. 2023 Jul 12;6(4):66. doi: 10.3390/mps6040066.
5
A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT.一项多中心、患者和评估者双盲、非劣效性、随机对照的 II 期临床试验，旨在比较标准和扭矩 Teno 病毒导向免疫抑制在移植后第一年的肾移植受者中的效果：TTVguideIT。
Trials. 2023 Mar 22;24(1):213. doi: 10.1186/s13063-023-07216-0.
6
Dietary lithium intake, graft failure and mortality in kidney transplant recipients.饮食锂摄入与肾移植受者移植物失败和死亡的关系。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1867-1879. doi: 10.1093/ndt/gfac340.
7
Ten-year incidence of post-transplant Diabetes Mellitus in renal transplant patients.肾移植患者移植后糖尿病的十年发病率。
Diab Vasc Dis Res. 2022 Nov-Dec;19(6):14791641221137352. doi: 10.1177/14791641221137352.
8
AIM2 as a putative target in acute kidney graft rejection.AIM2 作为急性肾移植排斥反应的潜在靶点。
Front Immunol. 2022 Sep 30;13:839359. doi: 10.3389/fimmu.2022.839359. eCollection 2022.
9
Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation.重新定义肾移植临床试验的风险分层和终点：欧洲器官移植学会向欧洲药品管理局提交提案的理由和方法。
Transpl Int. 2022 May 20;35:10142. doi: 10.3389/ti.2021.10142. eCollection 2022.
10
Molecular Aspects of Renal Immunology: Current Status and Future Perspectives.肾脏免疫学的分子方面：现状与未来展望。
Int J Mol Sci. 2022 Apr 6;23(7):4040. doi: 10.3390/ijms23074040.
本文引用的文献
1
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.移植患者中高度致敏者的 IgG 内肽酶。
N Engl J Med. 2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567.
2
Transplant trials with Tregs: perils and promises.Tregs的移植试验：风险与前景。
J Clin Invest. 2017 Jun 30;127(7):2505-2512. doi: 10.1172/JCI90598.
3
Anti-CD20 Blocker Rituximab in Kidney Transplantation.抗 CD20 阻断剂利妥昔单抗在肾移植中的应用。
Transplantation. 2018 Jan;102(1):44-58. doi: 10.1097/TP.0000000000001849.
4
Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.实体器官移植中的抗体介导性排斥反应：表现、机制及治疗方法
J Clin Invest. 2017 Jun 30;127(7):2492-2504. doi: 10.1172/JCI90597. Epub 2017 Jun 12.
5
HSCT-Based Approaches for Tolerance Induction in Renal Transplant.基于造血干细胞移植的肾移植耐受诱导方法。
Transplantation. 2017 Nov;101(11):2682-2690. doi: 10.1097/TP.0000000000001837.
6
Strategies for long-term preservation of kidney graft function.肾脏移植物功能的长期保护策略。
Lancet. 2017 May 27;389(10084):2152-2162. doi: 10.1016/S0140-6736(17)31283-7.
7
Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.肾移植中的细胞疗法：聚焦调节性T细胞
J Am Soc Nephrol. 2017 Jul;28(7):1960-1972. doi: 10.1681/ASN.2016111206. Epub 2017 May 2.
8
Donor-Specific Antibodies in Kidney Transplant Recipients.供者特异性抗体在肾移植受者中的作用。
Clin J Am Soc Nephrol. 2018 Jan 6;13(1):182-192. doi: 10.2215/CJN.00700117. Epub 2017 Apr 26.
9
Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time?不可接受的人类白细胞抗原：如何在免疫风险增加和等待时间之间权衡？
Nephrol Dial Transplant. 2017 May 1;32(5):745-747. doi: 10.1093/ndt/gfx028.
10
Steroid free immunosuppression is associated with enhanced Th1 transcripts in kidney transplantation.肾移植中无类固醇免疫抑制与Th1转录本增强相关。
Transpl Immunol. 2017 Jun;42:18-23. doi: 10.1016/j.trim.2017.03.001. Epub 2017 Mar 31.
Zotero 插件